

# BENCHMARK-FREE ALLOCATION PROFILE


## INVESTMENT OPPORTUNITY

Over long cycles, static balanced portfolios tend to provide attractive returns relative to risks. Markets, however, are inefficient, and asset prices often become disconnected from their long-term fair values leaving static portfolios susceptible to expensive assets and weak returns for extended periods. A valuation-sensitive, dynamic approach can improve long-term risk adjusted return and mitigate drawdowns.

## GMO APPROACH

- Valuation Discipline** We believe that the price paid for an asset is a critical driver of investment outcomes, making objective and disciplined valuation assessment essential
- Dynamic Allocation** We actively adjust exposures across and within asset classes based on valuation signals; therefore, the portfolio continually adapts to market conditions.
- Exploit Dislocations:** We take full advantage of market dislocations, including designing new strategies to capitalize on them as needed.
- Broad Toolkit:** We allocate across a spectrum of strategies spanning equities, rates, credit, and diverse alternative strategies. We are able to target specific regions, countries, styles, cohorts, and asset types to meet objectives and represent the best opportunities available in a particular environment.


## BENCHMARK-FREE ALLOCATION STRATEGY HAS DELIVERED SOLID RISK-ADJUSTED RETURNS



As of 9/30/25 | Source: GMO  
Inception date: 7/31/01

The chart above shows the past performance of the Benchmark-Free Allocation Composite (the "Composite"). Prior to January 1, 2012, the accounts in the Composite served as the principal component of a broader real return strategy. Beginning January 1, 2012, accounts in the composite have been managed as a standalone investment.

## WILLING TO BE DYNAMIC AND UNCONVENTIONAL




<sup>1</sup>Includes GMO's Resources and Climate Change strategies. <sup>2</sup>Total allocation to Equity Dislocation is 19.3% inclusive of exposure within Alternative Allocation. <sup>3</sup>The headline exposure to U.S. Treasury Notes should not be considered in isolation of the portfolio's overall duration profile inclusive of collateral and other exposures. <sup>4</sup>Combination of Alpha Only Fund and other private vehicles. The above information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy. Weightings are as of the date indicated and are subject to change. The groups indicated above represent exposures determined pursuant to proprietary methodologies and are subject to change over time. Totals may vary due to rounding.

## CONTACT US

For more information on this product please email us at [access@gmo.com](mailto:access@gmo.com) or reach out to your relationship manager.

## BENCHMARK-FREE ALLOCATION PROFILE



**July 2001—September 2025 | Source: GMO** \*Alpha Only is a market neutral portable alpha strategy. Cyclical Focus entered the portfolio in April 2020 as a long position and was reclassified as Equity Long/Short in May 2020. The above information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy. The groups indicated above represent exposures determined pursuant to proprietary methodologies and are subject to change over

## CONTACT US

For more information on this product please email us at [access@gmo.com](mailto:access@gmo.com) or reach out to your relationship manager.

# BENCHMARK-FREE ALLOCATION

## OVERVIEW

The GMO Benchmark-Free Allocation Strategy seeks to generate positive total return by allocating dynamically across asset classes, free from the constraints of traditional benchmarks.

The philosophy that underlies all of GMO's Asset Allocation investment strategies is the belief that, at times and in the short term, the pricing of asset classes can deviate from true intrinsic value, but mean reverts to appropriate valuation levels over the long term. GMO's proprietary 7-Year Asset Class Forecasts form the foundation of our investment process, providing a framework to assess the return opportunity embedded in different asset classes. We use that insight to allocate to what we believe are the most attractively priced asset classes.

## FACTS

Strategy Inception	31-Jul-01
Composite Inception	31-Jul-01
Total Assets	\$3.0bn USD
Index	CPI Index

## CUMULATIVE TOTAL RETURNS (USD, NET OF FEES, %)

	MTD	QTD	YTD	2024	2023	2022	2021	2020
Composite	1.29	6.09	15.77	4.35	13.58	-2.84	2.94	-2.44
Index	0.00	0.58	1.79	2.86	3.60	6.40	7.04	1.27

## RISK PROFILE (5-YEAR TRAILING)

Sharpe Ratio	0.56
Standard Deviation	8.11
Max Port. Drawdown (31-May-21 - 30-Sep-22)	-14.09

## ANNUALIZED TOTAL RETURNS (USD, NET OF FEES, %)

	1 Year	3 Years	5 Years	10 Years	ITD
Composite	12.57	13.95	7.66	5.34	7.77
Index	2.76	2.90	4.44	3.13	2.52

## PORTFOLIO MANAGEMENT



Ben Inker, CFA  
Joined GMO in 1992  
BA, Yale University



John Thorndike  
Joined GMO in 2015  
BA, Bowdoin College

**Risks:** Risks associated with investing in the Strategy may include: (1) Management and Operational Risk: the risk that GMO's investment techniques will fail to produce desired results, including annualized returns and annualized volatility; (2) Market Risk - Equities: the market price of equities may decline due to factors affecting the issuer, its industries, or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares; and (3) Non-U.S. Investment Risk: The market prices of many non-U.S. securities (particularly of companies tied economically to emerging countries) fluctuate more than those of U.S. securities. Many non-U.S. markets (particularly emerging markets) are less stable, smaller, less liquid, and less regulated than U.S. markets, and the cost of trading in those markets often is higher than it is in U.S. markets. This is not a complete list of risks associated with investing in the Strategy. Please contact GMO for more information.

**Performance Returns:** Returns shown for periods greater than one year are on an annualized basis. To obtain performance information to the most recent month-end, visit [www.gmo.com](http://www.gmo.com). **Performance data quoted represents past performance and is not predictive of future performance.** Net returns are presented after the deduction of a model advisory fee and incentive fee if applicable. These returns include transaction costs, commissions and withholding taxes on foreign income and capital gains and include the reinvestment of dividends and other income, as applicable. Fees paid by accounts within the composite may be higher or lower than the model fees used. **GMO LLC claims compliance with the Global Investment Performance Standards (GIPS®). A Global Investment Performance Standards (GIPS®) Composite Report is available at [www.gmo.com](http://www.gmo.com) by clicking the GIPS® Composite Report link in the documents section of the strategy page. GIPS® is a registered trademark owned by CFA Institute. CFA Institute does not endorse or promote this organization, nor does it warrant the accuracy or quality of the content contained herein. Actual fees are disclosed in Part 2 of GMO's Form ADV and are also available in each strategy's Composite Report.** Prior to January 1, 2012, the accounts in the Composite served as the principal component of a broader real return strategy. Beginning January 1, 2012, accounts in the composite have been managed as a standalone investment. Returns include a substantial, one-time litigation settlement recovery received on December 16, 2024. This event contributed 2.45% to 2024 annual performance, based on a representative account. Performance for other periods, including this date, was also positively impacted, sometimes materially. Without this recovery, performance would have been lower in both absolute terms and relative to the benchmark. Additional information is available upon request. The portfolio is actively-managed, is not managed relative to a benchmark and uses an index for performance comparison purposes only and, where applicable, to compute a performance fee.

## BENCHMARK-FREE ALLOCATION

## PORTFOLIO ALLOCATIONS (%)

<i>Asset Class</i>	<i>Exposure</i>
<b>EQUITY</b>	<b>49.0</b>
International Opportunistic Value	9.2
Japan Fundamental Value	6.1
Japan Small Value	3.0
Developed ex-US	6.2
US Opportunistic Value	5.0
Resource Equity	4.1
Developed ex-US Small Cap Value	5.2
Emerging Markets	10.2
<b>ALTERNATIVE STRATEGIES</b>	<b>27.9</b>
Equity Dislocation	14.7
Alternative Allocation	13.2
<b>FIXED INCOME</b>	<b>23.1</b>
ABS/Structured Products	2.0
US Treasury Notes	19.0
Emerging Debt	2.1

## EQUITY SECTORS (%)

<i>Sector</i>	<i>Portfolio</i>
Communication Services	4.9
Consumer Discretionary	11.3
Consumer Staples	5.9
Energy	7.3
Financials	22.8
Health Care	8.5
Industrials	17.0
Information Technology	11.4
Materials	7.9
Real Estate	1.8
Utilities	1.1

## EQUITY REGIONS (%)

<i>Region</i>	<i>Portfolio</i>
Japan	28.8
Emerging	22.5
Europe ex UK (Developed)	19.6
United States	13.0
Other International	9.7
United Kingdom	6.5

## EQUITY CHARACTERISTICS

	<i>Portfolio</i>
Price/Earnings - Hist 1 Yr Wtd Mdn	13.7x
Price/Book - Hist 1 Yr Wtd Avg	1.3x
Return on Equity - Hist 1 Yr Mdn	12.2%
Dividend Yield - Hist 1 Yr Wtd Avg	3.7%
Market Cap - Wtd Mdn Bil	12.7 USD

## EQUITY TOP COUNTRIES (%)

<i>Country</i>	<i>Portfolio</i>
Japan	28.8
United States	13.0
United Kingdom	6.5
Taiwan	5.8
Canada	5.1
France	3.7
China	3.1
South Korea	2.9
India	2.5
Netherlands	2.5

## FIXED INCOME CHARACTERISTICS

	<i>Portfolio</i>
Effective Duration	1.9

## FIXED INCOME CREDIT RATINGS (%)

	<i>%</i>
AAA	3.2
AA	86.1
A	0.7
BBB	1.7
BB	2.2
B	1.7
CCC	2.3
CC	0.2
C	0.2
D	0.6
NR	1.0

# BENCHMARK-FREE ALLOCATION

## IMPORTANT INFORMATION

**Index(es):** The CPI (Consumer Price Index) for All Urban Consumers US All Items is published monthly by the U.S. government as an indicator of changes in price levels (or inflation) paid by urban consumers for a representative basket of goods and services. CPI Index returns are typically reported on the 15th of the month. The CPI data reported may not include the most recent month-end which could impact the data that GMO has provided.

The above information is based on a representative account in the Strategy selected because it has the fewest restrictions and best represents the implementation of the Strategy.

For private bank intermediaries in Singapore and Hong Kong, these materials are intended for institutional and Accredited/Professional Investors Use Only.

## GLOSSARY

**Equity Characteristics:** Based on equity holdings. **Country Exposures:** Based on equity holdings. This portfolio continues to hold de minimis Russian exposure as a result of past positioning and ongoing illiquidity. GMO has suspended net new purchases of Russian securities firm-wide. **Credit Ratings:** The credit ratings above may encompass emerging debt, developed rates, and asset-backed exposure. Ratings for core portfolio holdings are derived by using the middle rating from Standard & Poor's, Moody's, and Fitch. Ratings for core holdings were adjusted during the January 2021 reporting period to conform with index provider methodology. Ratings for the emerging debt portion of the portfolio are derived by applying the Standard and Poor's or Moody's issue-level ratings (sequentially), and the S&P LT Foreign currency (FC) country issuer rating for the FC debt securities and/or S&P LT Local currency (LC) country issuer rating for LC securities where a security is not rated by either of the abovementioned credit rating agencies. Final credit ratings are expressed based upon Standard and Poor's ratings scale. Standard & Poor's rates securities from AAA (highest quality) to C (lowest quality), and D to indicate securities in default; some securities are not rated (NR). BB and below are considered below investment grade securities. Please refer to our website for additional information:

<https://www.gmo.com/americas/benchmark-disclaimers/> **Portfolio Allocations:** Weightings are as of the date indicated and are subject to change. The groups indicated above represent exposures determined pursuant to proprietary methodologies and are subject to change over time. Totals may vary due to rounding. **Region Exposures:** Based on equity holdings.

**Risk Statistics:** Risk profile data is net of fees. Sharpe Ratio is the return over the risk free rate per unit of risk. Std Deviation is a measure of the volatility of a portfolio. Drawdown is based on the portfolio's worst performance over the period based on monthly observations.

**Sector Exposures:** The Global Industry Classification Standard (GICS) is the exclusive intellectual property of MSCI Inc. (MSCI) and Standard & Poor's, a division of The McGraw-Hill Companies, Inc. (S&P). Neither MSCI, S&P, nor any third party makes any representations or warranties, express or implied, with respect to GICS or the results to be obtained by the use thereof, and expressly disclaim all warranties, including of merchantability and fitness for a particular purpose. Neither MSCI, S&P, nor any third party shall have any liability for any damages of any kind relating to the use of GICS. **Top Holdings:** Based on equity holdings. Holdings are subject to change and should not be considered a recommendation to buy individual securities. This portfolio continues to hold de minimis Russian exposure as a result of past positioning and ongoing illiquidity. GMO has suspended net new purchases of Russian securities firm-wide.

## ABOUT GMO

Founded in 1977, GMO is a global asset manager committed to delivering superior performance and advice to our clients. We are privately owned, which allows us to singularly focus on our sole business – achieving outstanding long-term client investment outcomes. Offering multi-asset, equity, fixed income, and alternative strategies, we invest with a long-term, valuation-based philosophical approach.

AMSTERDAM

BOSTON

LONDON

SAN FRANCISCO\*

SINGAPORE

SYDNEY

TOKYO\*\*

\*GMO's West Coast Hub is comprised of members of Investment, Global Client Relations, and other teams located in and around the Greater San Francisco area

\*\*Representative Office

[www.GMO.com](http://www.GMO.com)